Abstract: Methods are described for slowing or inhibiting the progression of heart failure in a mammalian subject suffering from chronic hypertension. The methods involve administering an ?PKC, ?1PKC, or ?IIPKC peptide inhibitor, examples of which are provided.

Abstract: Described are methods for reducing tumor metastasis in an animal by administering an inhibitor of a protein kinase C (PKC) isozyme.

Abstract: Peptides derived from the C2 regions of ?PKC and methods of use, thereof, are described. These peptides modulate the activity of ?PKC in an animal model of acute ischemic heart disease.

Abstract: Peptides derived from the C2 regions of ?PKC and methods of use, thereof, are described. These peptides modulate the activity of ?PKC in an animal model of acute ischemic heart disease.

Abstract: Methods are described for slowing or inhibiting the progression of heart failure in a mammalian subject suffering from chronic hypertension. The methods involve administering an ?PKC, ?1PKC, or ?IIPKC peptide inhibitor, examples of which are provided.

Abstract: Methods are described for slowing or inhibiting the progression of heart failure in a mammalian subject suffering from chronic hypertension. The methods involve administering an ?PKC, ?1PKC, or ?IIPKC peptide inhibitor, examples of which are provided.

Abstract: A peptide identified from the annexin V protein sequence and having the ability to modulate the activity of delta protein kinase C (PKC) is described. The peptide and variants thereof bind to delta PKC and are effective to regulate delta PKC mediated cellular responses. In particular the annexin V peptide is able to inhibit protein-protein interaction with delta PKC, blocking intracellular translocation of delta PKC. Inhibition of delta PKC translocation confers protection to tissue at risk of exposure to ischemia or hypoxia or to reperfusion injury.

Abstract: Described are methods for reducing tumor metastasis in an animal by administering an inhibitor of a protein kinase C (PKC) isozyme.

Abstract: The described compositions and methods relate to the suppression of inflammatory responses following allograft transplantation by administering an inhibitor of epsilon protein kinases c (?PKC) following transplantation.

Abstract: Peptides found within an annexin protein can be used to modulate the activity of a protein kinase C are described. More particularly, peptides within annexin I, V, and VI, as well as variants and conservatively modified variants thereof, are described, and use of these peptides to regulate cellular responses mediated by ?-protein kinase C, ?-protein kinase C, and ?-protein kinase C, respectively, are described.

Abstract: Peptides derived from the C2 regions of ?PKC and methods of use, thereof, are described. These peptides modulate the activity of ?PKC in an animal model of acute ischemic heart disease.

Abstract: Methods for maintaining the integrity of the blood-brain barrier are described. Compounds that act to inhibit the action of the delta isozyme of protein kinase C (PKC) to prevent disruption of the blood-brain barrier in hypertensive subjects are described, to, in one embodiment, decrease the likelihood of hypertension-induced stroke or hypertension-induced encephalopathy.

Abstract: Treatment methods for inhibiting tumor growth and angiogenesis are described. The methods involve treatment with an inhibitor of delta protein kinase C (?PKC) or an inhibitor of beta-II protein kinase C (?IIPKC), in an amount effective to decrease the rate of growth of a solid tumor and/or to inhibit tumor angiogenesis.